[News Space=Reporter seungwon lee] The 2026 JP Morgan Healthcare Conference (JPMHC), the world's largest pharmaceutical and bio investment conference, will be held from January 12 to 15 at the Westin St. Francis Hotel in San Francisco, USA, with approximately 1,500 companies and over 8,000 participants.

At this year's event, Korean companies such as Samsung BioLogics and Celltrion are expected to dominate the main track, the Grand Ballroom, capturing the attention of global investors. Amidst the announcements of mid- to long-term strategies by global big pharma and biotech companies, the lineup of noteworthy companies is drawing attention, from CDMO giants with cumulative orders exceeding $20 billion to ventures aiming for the technology export jackpot.

Main Track Stars: Samsung BioLogics and Celltrion

Samsung BioLogics has been officially invited for 10 consecutive years since 2017. On January 13th, at 3:00 PM, CEO John Lim will present "Excellence" in the Grand Ballroom. He will highlight the company's record of surpassing $20 billion (approximately 27 trillion won) in cumulative orders, standing shoulder to shoulder with big pharma giants like GSK, AstraZeneca, and Eli Lilly, as well as its acquisition of the Rockville, Maryland, U.S. plant for $280 million (approximately 414.7 billion won).

Celltrion, led by CEO Seo Jin-seok, is unveiling a strategy to enter the CDMO market and expand its similar product portfolio, based on the completion of its acquisition of the Eli Lilly plant in New Jersey, USA.

Asia Pacific Session: Alteogen, D&D Pharmatech, and Hugel

Alteogen, D&D Pharmatech, and Hugel will showcase their technological prowess at the APAC track on January 15th. D&D Pharmatech will present interim data from the Phase 2 clinical trial of DD01, a MASH treatment, while Alteogen will showcase its achievements under new CEO Jeon Tae-yeon and explore global partnerships. Hugel will emphasize its technology export potential, projecting it to extend its record of 21 trillion won in technology exports last year.

Unofficial Participation/Next Generation Management Points

About 10 Korean companies, including Hanmi Pharmaceutical, Yuhan Corporation, Samsung Bioepis, SK Biopharmaceuticals, and Lotte Biologics, will participate in the meeting.

SK Biopharmaceuticals CEO Choi Yoon-jung, the eldest daughter of SK Group Chairman Chey Tae-won, and the head of the Strategy Division, will lead the radiopharmaceutical (RPT) business, while Lotte Biologics CEO Shin Yoo-yeol and James Park, the eldest sons of Lotte Group Chairman Shin Dong-bin, will lead business meetings. On the global front, companies such as Merck, Pfizer, Novo Nordisk, The Cooper Companies, Waystar, and Penumbra are expected to attract investor attention with strategic presentations. Apharmaceuticaland bio industry insider commented, "JPMHC is not just a place to introduce technologies; it is a place to close actual deals. Securing a production base in the US for Korean companies is key to their global dominance." Attention is focused on whether the networking event will yield the next round of deals.